Four years after clinical trial sponsors were told to report summary results in the European Union, half of the registered studies remain unreported, although drug makers are doing a much better job at disclosure than other organizations, a new analysis finds.

Specifically, only 51 percent of more than 7,600 clinical trial results have so far been reported since the European Commission issued guidelines in 2014. However, 68 percent of trials sponsored by the pharmaceutical industry have reported results, while only 11 percent of trials sponsored by hospitals, academics, governments, and charities have done so, according to the analysis published in BMJ.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy